vs
Side-by-side financial comparison of Journey Medical Corp (DERM) and SIFCO INDUSTRIES INC (SIF). Click either name above to swap in a different company.
SIFCO INDUSTRIES INC is the larger business by last-quarter revenue ($24.0M vs $16.1M, roughly 1.5× Journey Medical Corp). SIFCO INDUSTRIES INC runs the higher net margin — 7.5% vs -7.8%, a 15.2% gap on every dollar of revenue. On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs 14.8%). Over the past eight quarters, Journey Medical Corp's revenue compounded faster (11.0% CAGR vs 8.1%).
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
SIFCO Industries, Inc. (SIFCO), is a global metal component manufacturer based in Cleveland, Ohio.
DERM vs SIF — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $16.1M | $24.0M |
| Net Profit | $-1.2M | $1.8M |
| Gross Margin | — | 21.6% |
| Operating Margin | -2.8% | 10.7% |
| Net Margin | -7.8% | 7.5% |
| Revenue YoY | 27.3% | 14.8% |
| Net Profit YoY | -182.0% | 177.3% |
| EPS (diluted) | $-0.04 | $0.29 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.1M | $24.0M | ||
| Q3 25 | $17.0M | $22.8M | ||
| Q2 25 | $15.0M | $22.1M | ||
| Q1 25 | $13.1M | $19.0M | ||
| Q4 24 | $12.6M | $20.9M | ||
| Q3 24 | $14.6M | $21.7M | ||
| Q2 24 | $14.9M | $22.0M | ||
| Q1 24 | $13.0M | $20.5M |
| Q4 25 | $-1.2M | $1.8M | ||
| Q3 25 | $-2.3M | $-429.0K | ||
| Q2 25 | $-3.8M | $3.4M | ||
| Q1 25 | $-4.1M | $-1.4M | ||
| Q4 24 | $1.5M | $-2.3M | ||
| Q3 24 | $-2.4M | $-443.0K | ||
| Q2 24 | $-3.4M | $72.0K | ||
| Q1 24 | $-10.4M | $-1.6M |
| Q4 25 | — | 21.6% | ||
| Q3 25 | — | 9.6% | ||
| Q2 25 | — | 26.7% | ||
| Q1 25 | — | 8.3% | ||
| Q4 24 | 82.3% | 4.4% | ||
| Q3 24 | 63.9% | 10.7% | ||
| Q2 24 | 56.0% | 12.3% | ||
| Q1 24 | 47.7% | 7.3% |
| Q4 25 | -2.8% | 10.7% | ||
| Q3 25 | -9.0% | -1.7% | ||
| Q2 25 | -19.2% | 14.8% | ||
| Q1 25 | -25.3% | -4.1% | ||
| Q4 24 | 17.7% | -9.2% | ||
| Q3 24 | -19.8% | -1.5% | ||
| Q2 24 | -19.7% | 0.7% | ||
| Q1 24 | -77.4% | -6.5% |
| Q4 25 | -7.8% | 7.5% | ||
| Q3 25 | -13.6% | -1.9% | ||
| Q2 25 | -25.3% | 15.4% | ||
| Q1 25 | -31.0% | -7.3% | ||
| Q4 24 | 12.1% | -11.1% | ||
| Q3 24 | -16.3% | -2.0% | ||
| Q2 24 | -22.6% | 0.3% | ||
| Q1 24 | -80.1% | -7.8% |
| Q4 25 | $-0.04 | $0.29 | ||
| Q3 25 | $-0.09 | $-0.07 | ||
| Q2 25 | $-0.16 | $0.56 | ||
| Q1 25 | $-0.18 | $-0.23 | ||
| Q4 24 | $0.10 | $-0.38 | ||
| Q3 24 | $-0.12 | $-0.07 | ||
| Q2 24 | $-0.17 | $0.01 | ||
| Q1 24 | $-0.53 | $-0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.1M | $1.1M |
| Total DebtLower is stronger | $25.3M | $39.0K |
| Stockholders' EquityBook value | $31.9M | $38.7M |
| Total Assets | $94.6M | $74.9M |
| Debt / EquityLower = less leverage | 0.79× | 0.00× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.1M | $1.1M | ||
| Q3 25 | $24.9M | $491.0K | ||
| Q2 25 | $20.3M | $2.0M | ||
| Q1 25 | $21.1M | $1.9M | ||
| Q4 24 | $20.3M | $3.1M | ||
| Q3 24 | $22.5M | $1.7M | ||
| Q2 24 | $23.9M | $3.4M | ||
| Q1 24 | $24.1M | $2.5M |
| Q4 25 | $25.3M | $39.0K | ||
| Q3 25 | $25.2M | $51.0K | ||
| Q2 25 | $25.1M | — | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $24.9M | — | ||
| Q3 24 | $19.8M | $0 | ||
| Q2 24 | $19.7M | $3.6M | ||
| Q1 24 | $14.7M | $4.1M |
| Q4 25 | $31.9M | $38.7M | ||
| Q3 25 | $25.9M | $36.9M | ||
| Q2 25 | $19.2M | $35.8M | ||
| Q1 25 | $21.5M | $32.4M | ||
| Q4 24 | $20.1M | $33.7M | ||
| Q3 24 | $10.9M | $30.4M | ||
| Q2 24 | $11.3M | $29.8M | ||
| Q1 24 | $13.0M | $29.7M |
| Q4 25 | $94.6M | $74.9M | ||
| Q3 25 | $85.2M | $73.4M | ||
| Q2 25 | $81.2M | $77.3M | ||
| Q1 25 | $85.0M | $78.8M | ||
| Q4 24 | $80.2M | $81.0M | ||
| Q3 24 | $64.0M | $104.6M | ||
| Q2 24 | $65.2M | $106.3M | ||
| Q1 24 | $66.6M | $104.2M |
| Q4 25 | 0.79× | 0.00× | ||
| Q3 25 | 0.97× | 0.00× | ||
| Q2 25 | 1.30× | — | ||
| Q1 25 | 1.16× | — | ||
| Q4 24 | 1.24× | — | ||
| Q3 24 | 1.81× | 0.00× | ||
| Q2 24 | 1.75× | 0.12× | ||
| Q1 24 | 1.13× | 0.14× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | $8.1M |
| Free Cash FlowOCF − Capex | — | $8.0M |
| FCF MarginFCF / Revenue | — | 33.3% |
| Capex IntensityCapex / Revenue | — | 0.4% |
| Cash ConversionOCF / Net Profit | — | 4.51× |
| TTM Free Cash FlowTrailing 4 quarters | — | $11.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.3M | $8.1M | ||
| Q3 25 | $-2.4M | $726.0K | ||
| Q2 25 | $-942.0K | $371.0K | ||
| Q1 25 | $-2.8M | $2.8M | ||
| Q4 24 | $2.2M | $-3.8M | ||
| Q3 24 | $-1.2M | $857.0K | ||
| Q2 24 | $-5.2M | $382.0K | ||
| Q1 24 | $-5.0M | $-3.2M |
| Q4 25 | — | $8.0M | ||
| Q3 25 | — | $566.0K | ||
| Q2 25 | — | $310.0K | ||
| Q1 25 | — | $2.7M | ||
| Q4 24 | — | $-3.9M | ||
| Q3 24 | — | $580.0K | ||
| Q2 24 | — | $-175.0K | ||
| Q1 24 | — | $-3.9M |
| Q4 25 | — | 33.3% | ||
| Q3 25 | — | 2.5% | ||
| Q2 25 | — | 1.4% | ||
| Q1 25 | — | 14.1% | ||
| Q4 24 | — | -18.8% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | -0.8% | ||
| Q1 24 | — | -18.9% |
| Q4 25 | — | 0.4% | ||
| Q3 25 | — | 0.7% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | 0.8% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.5% | ||
| Q1 24 | — | 3.3% |
| Q4 25 | — | 4.51× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.11× | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.46× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 5.31× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
SIF
| Fixed Wing Aircraft Revenue | $10.5M | 44% |
| Commercial Revenue | $8.7M | 36% |
| Commercial Product And Other Revenue | $2.8M | 12% |
| Commercial Space | $1.1M | 5% |
| Other | $840.0K | 4% |
